Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

S. Wise · SciRah

Researcher profile · Semantic Scholar

S. Wise

Share profile

S. Wise — researcher profile on SciRah

h-index: 21
Works: 91
Citations: 2,305

Most-cited papers

Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.
Sheng-Bin Peng, J. Henry, M. Kaufman, Wei-Ping Lu +26 more
2015Cancer Cell269 citations Open access
Semantic Scholar
Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants.
Bryan D. Smith, M. Kaufman, Wei-Ping Lu, Anu Gupta +25 more
2019Cancer Cell241 citations Open access
Semantic Scholar
Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone.
H. Camp, O. Li, S. Wise, Y. Hong +4 more
2000Diabetes235 citations
Semantic Scholar
cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype
Leia M. Smith, S. Wise, D. Hendricks, A. Sabichi +4 more
1999Oncogene223 citations Open access
Semantic Scholar
Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036
W. Chan, S. Wise, M. Kaufman, Y. Ahn +23 more
2011Cancer Cell216 citations Open access
Semantic Scholar
The selective Tie2 inhibitor rebastinib blocks recruitment and function of Tie2Hi macrophages in breast cancer and pancreatic neuroendocrine tumors
A. Harney, G. Karagiannis, Jeanine Pignatelli, Bryan D. Smith +16 more
2017Molecular Cancer Therapeutics125 citations Open access
Semantic Scholar
Troglitazone, an antidiabetic agent, inhibits cholesterol biosynthesis through a mechanism independent of peroxisome proliferator-activated receptor-gamma.
Ming-Han Wang, S. Wise, Todd Leff, Ti-zhi Su
1999Diabetes119 citations
Semantic Scholar
c-Jun Can Mediate Androgen Receptor-induced Transactivation*
Athanasios Bubulya, S. Wise, Xi-Qiang Shen, Lori A. Burmeister +1 more
1996Journal of Biological Chemistry115 citations Open access
Semantic Scholar
The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile
C. Eide, Lauren T. Adrian, J. Tyner, Mary Mac Partlin +8 more
2011Cancer Research101 citations Open access
Semantic Scholar
AXL regulates mesothelioma proliferation and invasiveness
Wen-Bin Ou, J. Corson, D. Flynn, W.-P. Lu +4 more
2011Oncogene92 citations Open access
Semantic Scholar
Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells.
J. Henry, M. Kaufman, Sheng-Bin Peng, Y. Ahn +29 more
2015Journal of Medicinal Chemistry81 citations Open access
Semantic Scholar
Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2
Bryan D. Smith, M. Kaufman, Cynthia Leary, B. A. Turner +19 more
2015Molecular Cancer Therapeutics73 citations Open access
Semantic Scholar
Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages
Bryan D. Smith, M. Kaufman, S. Wise, Y. Ahn +11 more
2021Molecular Cancer Therapeutics55 citations Open access
Semantic Scholar
Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia
J. Cortes, M. Talpaz, Hedy P. Smith, D. Snyder +12 more
2016Haematologica49 citations Open access
Semantic Scholar
Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT).
T. Caldwell, Yu Mi Ahn, Stacie L. Bulfer, Cynthia Leary +9 more
2022Bioorganic & Medicinal Chemistry Letters44 citations
Semantic Scholar
Identification of domains of c-Jun mediating androgen receptor transactivation
S. Wise, Lori A. Burmeister, Xiao-feng Zhou, Athanasios Bubulya +3 more
1998Oncogene41 citations Open access
Semantic Scholar
Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region.
Y. Ahn, M. Clare, C. Ensinger, M. Hood +16 more
2010Bioorganic & Medicinal Chemistry Letters33 citations Open access
Semantic Scholar
Targeting the KIT Activating Switch Control Pocket: A Novel Mechanism to Inhibit Neoplastic Mast Cell Proliferation and Mast Cell Activation
Yun Bai, G. Bandara, E. Chan, I. Marić +8 more
2012Leukemia29 citations Open access
Semantic Scholar
Switch Pocket Inhibitors of the ABL Tyrosine Kinase: Distinct Kinome Inhibition Profiles and in Vivo Efficacy in Mouse Models of CML and B-Lymphoblastic Leukemia Induced by BCR-ABL T315I
R. Van Etten, W. Chan, V. Zaleskas, C. Walz +6 more
200825 citations
Semantic Scholar
DCC-2036: A Novel Switch Pocket Inhibitor of ABL Tyrosine Kinase with Therapeutic Efficacy Against BCR-ABL T315I In Vitro and in a CML Mouse Model.
R. Van Etten, W. Chan, V. Zaleskas, Peter Evangelista +6 more
200724 citations
Semantic Scholar
A Phase 1 Study of DCC-2036, a Novel Oral Inhibitor of BCR-ABL Kinase, in Patients with Philadelphia Chromosome Positive (Ph+) Leukemias Including Patients with T315I Mutation
J. Cortes, M. Talpaz, H. Kantarjian, Hedy P. Smith +7 more
201121 citations
Semantic Scholar
Abstract 2690: DCC-2618 is a potent inhibitor of wild-type and mutant KIT, including refractory Exon 17 D816 KIT mutations, and exhibits efficacy in refractory GIST and AML xenograft models
Bryan D. Smith, M. Hood, S. Wise, M. Kaufman +4 more
201518 citations
Semantic Scholar
In vitro activity of novel KIT/PDGFRA switch pocket kinase inhibitors against mutations associated with drug-resistant GI stromal tumors.
M. Heinrich, S. Wise, M. Hood, Bryan D. Smith +6 more
201015 citations
Semantic Scholar
Discovery of Acyl Ureas as Highly Selective Small Molecule CSF1R Kinase Inhibitors.
T. Caldwell, M. Kaufman, S. Wise, Yu Mi Ahn +11 more
2022Bioorganic & Medicinal Chemistry Letters9 citations Open access
Semantic Scholar
Examination of Edge Effects with Different Storage Conditions of Preplated Dimethyl Sulfoxide Nanospots in ChemLib 1,536- and 3,456-Well Assay-Ready Plates
B. A. Turner, Brad P Evans, Tania T. Pearson, T. Braden +1 more
2008Assay and drug development technologies7 citations Open access
Semantic Scholar
Abstract 790: Altiratinib is a potent inhibitor of TRK kinases and is efficacious in TRK-fusion driven cancer models
Bryan D. Smith, Cynthia Leary, B. A. Turner, M. Kaufman +4 more
20155 citations
Semantic Scholar
Activity of Allosteric, Switch-Pocket, ABL/FLT3 Kinase Inhibitor DCC2036 Against Cultured and Primary AML Progenitors with FLT-ITD or FLT3 Kinase Domain Mutations
W. Fiskus, Catherine C. Smith, Jacqueline E. Smith, S. Wise +11 more
20115 citations
Semantic Scholar
Simultaneous Screening of Multiple Bacterial tRNA Synthetases Using an Escherichia coli S30-Based Transcription and Translation Assay
M. Dermyer, S. Wise, T. Braden, T. Holler
2007Assay and drug development technologies5 citations Open access
Semantic Scholar
Abstract 2619: Combination of ECP1014 and anti-PD-L1 reduces tumor growth in the CT26 murine colon carcinoma model of a cold tumor
B. Sandage, J. Talley, E. Martinez, M. Franklin +6 more
20173 citations
Semantic Scholar
Activity of novel RET inhibitors against RET genotypes associated with medullary thyroid cancer.
A. Gramza, J. Patterson, J. Peters, M. Kaufman +2 more
20103 citations
Semantic Scholar
The impact of single gene testing (SGT) on subsequent comprehensive genomic profiling (CGP) success in community oncology practice for advanced non-small cell lung cancer (NSCLC): Results from a prospective observational reference laboratory testing program.
M. Nesline, P. DePietro, Maureen E. Cooper, Shengle Zhang +16 more
2023Journal of Clinical Oncology2 citations
Semantic Scholar
Effect of homologous recombination deficient (HRD) breast cancers on a distinct immune marker phenotype by comprehensive genomic and immune profiling (CGIP).
H. Ko, S. Pabla, M. Nesline, K. Strickland +12 more
2023Journal of Clinical Oncology2 citations
Semantic Scholar
Abstract 5691: Evaluation of immunomodulatory agents in classically immunologically 'cold' cancers using syngeneic mouse models of breast and ovarian cancer
D. Daniel, S. Urs, Kevin Guley, S. Krueger +7 more
2018Immunology2 citations
Semantic Scholar
Abstract A53: The specific FMS kinase inhibitor, DCC-3014, durably inhibits FMS kinase in vivo and blocks cancer bone invasiveness
Bryan D. Smith, M. Kaufman, Cynthia Leary, M. Hood +5 more
20152 citations
Semantic Scholar
Abstract PR01: Rebastinib, a selective TIE2 kinase inhibitor, decreases TIE2-expressing macrophages, reduces metastasis, and increases survival in murine cancer models
D. Flynn, M. Kaufman, Cynthia Leary, M. Hood +5 more
20152 citations
Semantic Scholar
Abstract DDT02-02: Identification of LY3009120 as a pan inhibitor of Raf isoforms and dimers with minimal paradoxical activation and activities against BRaf or Ras mutant tumor cells
Sheng-Bin Peng, J. Henry, M. Kaufman, Wei-Ping Lu +17 more
20142 citations
Semantic Scholar
Abstract B78: Rebastinib, a small molecule TIE2 kinase inhibitor, prevents primary tumor growth and lung metastasis in the PyMT breast cancer model
Bryan D. Smith, M. Hood, M. Kaufman, M. Berger +2 more
20132 citations
Semantic Scholar
Abstract P4-15-12: Rebastinib in combination with eribulin ablates TIE2-expressing macrophages, reduces metastasis, and increases survival in the PyMT metastatic breast cancer model
Bd Smith, CB Leary, M. Kaufman, M. Hood +6 more
20132 citations
Semantic Scholar
Sequential Assessment of Troponin in the Diagnosis of Myocardial Infarction
B. Edwards, I. Washington, L. Pretlow, G. Passmore +2 more
2013American Society for Clinical Laboratory Science2 citations Open access
Semantic Scholar
Comparison of immune microenvironment between primary and metastatic breast tumors.
H. Ko, S. Pabla, M. Nesline, S. Gandhi +13 more
2023Journal of Clinical Oncology1 citations
Semantic Scholar
Abstract 283: Reconstructed plate-based 3D screening assays that predict in vivo responses
S. Urs, Michael Steffey, Ying Qu, M. Ryou +2 more
2022Cancer Research1 citations
Semantic Scholar
Abstract 1928: Radiation response in preclinical orthotopic models of brain cancer
E. Trachet, S. Urs, A. Wong, S. Wise +1 more
2019Tumor Biology1 citations Open access
Semantic Scholar
Design and Validation of a Survey Questionnaire for the Assessment of Physician Transfusion Medicine Knowledge
Ibsa Abdi, Lauren E. Gagnon, S. Wise, G. Passmore
2017American Society for Clinical Laboratory Science1 citations Open access
Semantic Scholar
Preclinical assessment of anti-tumor activity and immune response in syngeneic tumor models
M. Franklin, M. Thayer, D. Draper, D. Saims +1 more
20161 citations
Semantic Scholar
Abstract 4915: Evaluation of the immune response following treatment with anti-CTLA-4 antibody, radiation therapy or the combination in a murine model of breast cancer
M. Franklin, M. Thayer, D. Draper, D. Saims +1 more
20161 citations
Semantic Scholar
The crystal structure of human abl1 kinase domain T315I mutant in complex with DCC-2036
W. Chan, S. Wise, M. Kaufman, Y. Ahn +23 more
20111 citations
Semantic Scholar
A New BCR-ABL1 Mutation (L248R) Is Highly Resistant to Imatinib, Bosutinib, Nilotinib and Dasatinib, but Can Be Inhibited by AP-24534 and DCC-2036
S. Redaelli, L. Mologni, Roberta Rostagno, R. Piazza +4 more
20101 citations
Semantic Scholar
Activation switch pocket inhibitors target the T315I mutant of BCR-ABL
T. O'Hare, C. Eide, S. Wise, Bryan D. Smith +3 more
20081 citations
Semantic Scholar
Abstract 37: A novel technique to preclinically assess the ability of targeted therapies to inhibit both primary and metastatic non small cell lung carcinoma
E. Trachet, S. Wise
2023Cancer Research0 citations
Semantic Scholar
Analysis of recurrent research pathways for assessing and improving effectiveness in life sciences laboratories
E. A. Balas, C. Patel, Ben Ewing, Nauka Patel +3 more
2023medRxiv0 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

D. Flynn×22
Invite
D. Flynn — researcher profile on SciRah
Bryan D. Smith×21
Invite
Bryan D. Smith — researcher profile on SciRah
M. Kaufman×20
Invite
M. Kaufman — researcher profile on SciRah
M. Hood×14
Invite
M. Hood — researcher profile on SciRah

×13

Invite

Wei-Ping Lu — researcher profile on SciRah

Subha Vogeti×9

Invite

Subha Vogeti — researcher profile on SciRah

Thomas J. Rutkoski×9

Invite

Thomas J. Rutkoski — researcher profile on SciRah

Lakshminarayana Vogeti×9

Invite

Lakshminarayana Vogeti — researcher profile on SciRah

Lawrence E. Chun×8

Invite

Lawrence E. Chun — researcher profile on SciRah

Cynthia Leary×8

Invite

Cynthia Leary — researcher profile on SciRah

Invite

Y. Ahn — researcher profile on SciRah

Invite

T. Caldwell — researcher profile on SciRah